Neurocrine Biosciences (NBIX) Shares are Up 9.78%

Neurocrine Biosciences (NBIX) : Traders are bullish on Neurocrine Biosciences (NBIX) as it has outperformed the S&P 500 by a wide margin of 13.48% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 9.2%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 9.78% in the last 1 week, and is up 11.18% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

The stock has recorded a 20-day Moving Average of 7.87% and the 50-Day Moving Average is 9.56%.The 200 Day SMA reached 18.22% Neurocrine Biosciences Inc. is up 22.06% in the last 3-month period. Year-to-Date the stock performance stands at -4.54%.


Neurocrine Biosciences (NBIX) : 8 Wall Street analysts covering Neurocrine Biosciences (NBIX) believe that the average level the stock could reach for the short term is $70. The maximum price target given is $96 and the minimum target for short term is around $57, hence the standard deviation is calculated at $13.05.

For the current week, the company shares have a recommendation consensus of Buy. Neurocrine Biosciences (NASDAQ:NBIX): The stock opened at $52.75 and touched an intraday high of $54.13 on Friday. During the day, the stock corrected to an intraday low of $52.51, however, the bulls stepped in and pushed the price higher to close in the green at $54 with a gain of 2.47% for the day. The total traded volume for the day was 1,146,944. The stock had closed at $54 in the previous trading session.

Neurocrine Biosciences, Inc. is engaged in the development of pharmaceutical products focused on neurological and endocrine based diseases and disorders. The Companys two lead late-stage clinical programs are elagolix, a gonadotropin releasing hormone (GnRH) antagonist for womens health that is partnered with AbbVie Inc. (AbbVie), and a vesicular monoamine transporter 2 (VMAT2) inhibitor for the treatment of movement disorders. elagolix is in clinical trials for the treatment of Endometriosis and Uterine Fibroids. VMAT2 (NBI-98854) is a VMAT2 inhibitor in clinical trials for the treatment of tardive dyskinesia. Corticotropin-Releasing Factor (CRF) receptor antagonist (NBI-77860) is indicated for the treatment of Classic Congenital Adrenal Hyperplasia. NBI-77860 is a selective, orally-active, non-peptide CRF receptor antagonist.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.